At GEA we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product life-cycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
Our solution for continuous tableting lines is ConsiGma®, a 6 sigma-inspired manufacturing platform, incorporating different technologies to produce oral solid dosage forms in a continuous, cost-efficient way:
Showing 4 of 8
The ConsiGma® CF20 test rig is a standalone module that allows you to characterize the feeding behavior of your products during the early stages of R&D.
An indispensable part of the ConsiGma portfolio, the Conductor control system architecture ensures smooth operation and communication between the different elements of a pharmaceutical continuous manufacturing line
A highly integrated solution for continuous linear blending and direct compression, the ConsiGma® DC-LB lines offer all the advantages of continuous manufacturing: supply chain agility, small footprint, controlled blending and compression and improved quality.
Designed to achieve optimal blending results, the ConsiGma® DB modules facilitate the testing of dosing and blending operations and can be integrated with any continuous up- or downstream process.
GEA AddCool® installation cuts CO2 emissions associated with the operation of a spray dryer plant by 1,500 tons per year at Arla’s milk powder factory in Svenstrup, Denmark.
On Sept. 30, 2025, GEA rang the opening bell at the Frankfurt Stock Exchange, a symbolic moment that highlighted the company’s inclusion in Germany’s leading stock index, the DAX.
GEA’s new corporate headquarters in the up-and-coming Derendorf neighborhood of Düsseldorf, Germany, brings together people, ideas and expertise under one roof. With its open spaces, green terraces and energy-efficient design, the building reflects the company’s commitment to collaboration and sustainability.